Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma
Brief Summary: This randomized phase II trial studies different combinations of bevacizumab, temsirolimus, and sorafenib tosylate to see how well they work compared with bevacizumab alone in treating patients with kidney cancer that has spread to other places in the body. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab and sorafenib tosylate may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving different combinations of bevacizumab, sorafenib tosylate, and temsirolimus may be more effective than bevacizumab alone in treating metastatic kidney cancer.


Options:
A: Arm Label: Sorafenib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib+Pazopanib | Arm Label: Pazopanib followed by Sorafenib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib+Sorafenib | Intervention Type: DRUG; Name: Sorafenib+Pazopanib; Assigned to Arm(s): Sorafenib followed by pazopanib | Intervention Type: DRUG; Name: Pazopanib+Sorafenib; Assigned to Arm(s): Pazopanib followed by Sorafenib
B: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm
C: Arm Label: Arm A (sunitinib malate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sunitinib Malate | Arm Label: Arm B (sorafenib tosylate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sorafenib Tosylate | Arm Label: Arm C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm B (sorafenib tosylate, placebo) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm A (sunitinib malate, placebo)
D: Arm Label: Arm A (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study | Arm Label: Arm B (bevacizumab and temsirolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Temsirolimus | Arm Label: Arm C (bevacizumab and sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm D (sorafenib tosylate and temsirolimus); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate, Drug: Temsirolimus | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm B (bevacizumab and temsirolimus), Arm D (sorafenib tosylate and temsirolimus)

Answer: D